{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:54:56Z","timestamp":1782276896849,"version":"3.54.5"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100007338","name":"All India Institute of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007338","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clgc.2024.102073","type":"journal-article","created":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T17:39:29Z","timestamp":1710351569000},"page":"102073","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Effect of Topical Urea for Secondary Prophylaxis of Hand Foot Skin Reaction in Renal Cell Cancer Patients on Sunitinib Therapy"],"prefix":"10.1016","volume":"22","author":[{"given":"Syed Shariq","family":"Naeem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit Kumar","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.L.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Velpandian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Batra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Pramanik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2880-9330","authenticated-orcid":false,"given":"Saumya","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2024.102073_bib0001","unstructured":"\u201cCommon Terminology Criteria for Adverse Events (CTCAE) Version 5. Published: November 27, 2017. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute\u201d, 2017. Available at: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_60 (Accessed: April 4, 2021)."},{"issue":"4","key":"10.1016\/j.clgc.2024.102073_bib0002","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s40257-016-0197-1","article-title":"Multikinase inhibitor-induced hand-foot skin reaction: a review of clinical presentation, pathogenesis, and management","volume":"17","author":"Chanprapaph","year":"2016","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"10.1016\/j.clgc.2024.102073_bib0003","first-page":"e61","article-title":"The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life","volume":"11","author":"Nardone","year":"2012","journal-title":"J Drugs Dermatol. JDD"},{"issue":"6","key":"10.1016\/j.clgc.2024.102073_bib0004","first-page":"1827","article-title":"Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature","volume":"23","author":"Massey","year":"2015","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"issue":"4","key":"10.1016\/j.clgc.2024.102073_bib0005","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jaad.2014.03.019","article-title":"Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management","volume":"71","author":"Miller","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102073_bib0006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13555-015-0068-3","article-title":"Keratolytics and emollients and their role in the therapy of psoriasis: a systematic review","volume":"5","author":"Jacobi","year":"2015","journal-title":"Dermatol Ther"},{"issue":"6","key":"10.1016\/j.clgc.2024.102073_bib0007","first-page":"1585","article-title":"Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials","volume":"22","author":"Macedo","year":"2014","journal-title":"Support Care Cancer"},{"issue":"7","key":"10.1016\/j.clgc.2024.102073_bib0008","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1634\/theoncologist.2014-0219","article-title":"The hand-foot skin reaction and quality of life questionnaire: an assessment tool for oncology","volume":"20","author":"Anderson","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2024.102073_bib0009","first-page":"95","article-title":"BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95\/98\/NT","volume":"41","author":"Hall","year":"1999","journal-title":"Nucl Acids Symp Ser"},{"issue":"1","key":"10.1016\/j.clgc.2024.102073_bib0010","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/bib\/5.1.82","article-title":"Analysis for free: comparing programs for sequence analysis","volume":"5","author":"Tippmann","year":"2004","journal-title":"Brief Bioinform"},{"issue":"35","key":"10.1016\/j.clgc.2024.102073_bib0011","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1200\/JCO.2010.31.1431","article-title":"Placebo-controlled trial to determine the effectiveness of a urea\/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5","volume":"28","author":"Wolf","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"8","key":"10.1016\/j.clgc.2024.102073_bib0012","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1200\/JCO.2013.52.9651","article-title":"Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma","volume":"33","author":"Ren","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102073_bib0013","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2340\/000155551774446","article-title":"An experimental study of irritant effects of urea in different vehicles","volume":"177","author":"Agner","year":"1992","journal-title":"Acta Derm Venereol Suppl Stockh"},{"issue":"suppl 3","key":"10.1016\/j.clgc.2024.102073_bib0014","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000088478","article-title":"VEGF as a key mediator of angiogenesis in cancer","volume":"69","author":"Carmeliet","year":"2005","journal-title":"Oncology"},{"issue":"1","key":"10.1016\/j.clgc.2024.102073_bib0015","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/1756-9966-29-95","article-title":"Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib","volume":"29","author":"Jain","year":"2010","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clgc.2024.102073_bib0016","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/cncr.27705","article-title":"Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma","volume":"119","author":"Lee","year":"2013","journal-title":"Cancer"},{"issue":"15_suppl","key":"10.1016\/j.clgc.2024.102073_bib0017","doi-asserted-by":"crossref","first-page":"e15622","DOI":"10.1200\/jco.2015.33.15_suppl.e15622","article-title":"Association of single nucleotide polymorphisms (SNP) in STAT3 gene with hand-foot skin reaction in metastatic renal cell carcinoma patients treated with multi-kinase inhibitor","volume":"33","author":"Yamamoto","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.clgc.2024.102073_bib0018","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/psp4.12210","article-title":"Population modeling integrating pharmacokinetics, pharmacodynamics, pharmacogenetics, and clinical outcome in patients with sunitinib-treated cancer","volume":"6","author":"Diekstra","year":"2017","journal-title":"CPT Pharmacomet Syst Pharmacol."},{"issue":"3","key":"10.1016\/j.clgc.2024.102073_bib0019","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1248\/bpb.b14-00636","article-title":"Pharmacokinetic-pharmacodynamic analysis of sunitinib-induced thrombocytopenia in Japanese patients with renal cell carcinoma","volume":"38","author":"Nagata","year":"2015","journal-title":"Biol Pharm Bull"},{"issue":"5","key":"10.1016\/j.clgc.2024.102073_bib0020","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/bcp.12550","article-title":"Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662","volume":"79","author":"Yu","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"18_suppl","key":"10.1016\/j.clgc.2024.102073_bib0021","doi-asserted-by":"crossref","first-page":"5027-5027","DOI":"10.1200\/jco.2007.25.18_suppl.5027","article-title":"Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): a population pharmacokinetic\/pharmacodynamic (PKPD) approach","volume":"25","author":"Houk","year":"2007","journal-title":"J Clin Oncol"},{"issue":"38","key":"10.1016\/j.clgc.2024.102073_bib0022","doi-asserted-by":"crossref","first-page":"25277","DOI":"10.18632\/oncotarget.25423","article-title":"Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients","volume":"9","author":"Numakura","year":"2018","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.clgc.2024.102073_bib0023","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.bjc.6604456","article-title":"Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer","volume":"99","author":"van der Veldt","year":"2008","journal-title":"Br J Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324000442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324000442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T08:00:48Z","timestamp":1717660848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324000442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1558767324000442"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102073","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Effect of Topical Urea for Secondary Prophylaxis of Hand Foot Skin Reaction in Renal Cell Cancer Patients on Sunitinib Therapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102073"}}